Over the past decades, implementation of international treatment protocols, including those designed by the International Society of Pediatric Oncology (SIOP), has improved overall survival of patients with Wilms tumors (WT) to more than 90% for local disease. Still, 15% to 50% of WT patients with suffer from relapses. To improve relapsed WT management, shared international protocols stratify WT (relapse) patients into risk groups based on prognostic factors. Adequate treatment regimens are assigned in accordance with these risk groups. This project is focused on the evaluation of the current prognostic factors for tumor relapse, survival after relapse in the different risk groups, and the effect of the corresponding relapse treatment. In addition, we culture tumor organoids of (primary and) relapsed WT tissue. Drug screens are performed on these organoids to determine effective (patient specific) treatment options and unravel targets for therapy.
Phone 088 97 25 633